Company Announcements

AGM Results

Source: RNS
RNS Number : 8512N
Uniphar PLC
09 May 2024
 

AGM Results

 

Dublin, London | 9 May 2024

 

 

Uniphar plc (the Company) is pleased to announce that at its Annual General Meeting held at 11.00 a.m. today, 9 May 2024, each of the resolutions set out in the Notice of Annual General Meeting circulated to shareholders and made available on the Company's website, www.uniphar.ie, were duly passed without amendment.

 

Details of votes cast are set out below:

 

 

 

RESOLUTION

For

For %

Against

Against

%

Withheld

1

Financial Statements and Reports

142,776,909

100

-

0

1,659,778

2

Final Dividend of €3.2m

144,436,687

100

-

0

-

3(a)

Re-elect Ger Rabbette

133,691,402

92.56

10,745,283

7.44

2

3(b)

Re-elect Tim Dolphin

143,757,800

99.53

678,887

0.47

-

3(c)

Re-elect Paul Hogan

143,473,422

99.35

938,265

0.65

25,000

3(d)

Re-elect Sue Webb

144,049,623

99.77

333,788

0.23

53,276

3(e)

Re-elect Jim Gaul

138,288,164

95.78

6,095,247

4.22

53,276

3(f)

Re-elect Liz Hoctor

144,320,340

99.94

91,347

0.06

25,000

3(g)

Re-elect Maurice Pratt

141,968,268

98.29

2,468,417

1.71

2

3(h)

Re-elect Valerie Sick

144,143,411

99.83

240,000

0.17

53,276

4

Remuneration of Auditors

119,304,023

95.49

5,630,519

4.51

19,502,145

5

Authority to allot relevant securities

125,835,071

87.14

18,573,338

12.86

28,278

6

Disapplication of pre-emption rights in specified circumstances

143,264,607

99.19

1,172,080

0.81

-

7

Disapplication of pre-emption rights in additional circumstances

119,856,072

83.18

24,242,889

16.82

337,726

8

Authorise market purchases of the Company's Ordinary Shares

143,853,843

100

-

0

582,844

9

Re-issuance of Treasury Shares

142,676,687

98.78

1,760,000

1.22

-

 

 

 

--- ENDS ---

 

 



 

Contact Details

Uniphar Group

 

Tel: +353 (0) 1 428 7777

Allan Smylie, Head of Strategy and IR

 

Davy (Joint Corporate Broker, Nominated Advisor and

Euronext Growth Listing Sponsor)

 

Tel: +353 (0) 1 679 6363

Daragh O'Reilly

Niall Gilchrist

Ivan Murphy

 

 

 

RBC Capital Markets (Joint Corporate Broker)

 

Tel: +44 (0) 20 7653 4000

Jamil Miah

Rupert Walford

 

 

 

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

 

Tel: +44 (0) 20 7710 7600

Matt Blawat

Ben Maddison

Francis North

 

 

 

Q4 PR

 

Tel: +353 (0) 1 475 1444

Iarla Mongey, Public Relations Advisor to Uniphar Group

 

 

About Uniphar plc 

Headquartered in Dublin, Ireland, the Uniphar Group is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. The Group is active in Europe, North America, APAC and MENA and delivers to 160+ countries.

 

The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth, and profitability.

 

Uniphar Supply Chain & Retail

Uniphar Supply Chain & Retail is the leading pharmaceutical wholesaler in Ireland with a growing symbol group offering of retail pharmacies. The Group's strategy for Uniphar Supply Chain & Retail is to grow our wholesale market share, our symbol group network and our own brand, in-licenced and consumer products portfolio.

 

Uniphar Medtech

Uniphar Medtech is a leading Pan-European medical device distributor and solutions partner. The Group's strategy for Uniphar Medtech is to grow our service offering across Europe and expand our addressable market by serving new specialities and new manufacturers.

 

Uniphar Pharma

Uniphar Pharma operates a global business with high value services across the lifecycle of a pharmaceutical product. We enable pharma and biotech companies to bring innovative medicines to global markets and provide healthcare professionals with access to medicines they can't source through traditional channels. Our strategy is to build a leading platform to provide the specialist support and expertise needed to improve access to these medicines.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGQKCBBNBKDQPK